Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01690689
Other study ID # ALCR-120412-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 2012
Est. completion date March 31, 2017

Study information

Verified date December 2020
Source Episurf Medical Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose is to assess the safety profile and performance of a femoral resurfacing implant for localized chondral lesions.


Description:

The implant's safety profile will be assessed by incidence of any subject having any of the seven identified implant-related clinical undesirable side effects. This will be analyzed with a one-side exact binomial test on significance level 0.05, at 24 months post-operatively.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date March 31, 2017
Est. primary completion date March 31, 2017
Accepts healthy volunteers No
Gender All
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria: 1. Male or female 2. Age 30 = 65 years 3. Chondral defects of the femoral cartilage ICRS grade 3 (severely abnormal cartilage defects > 50% of the cartilage depth) or grade 4 (severely abnormal, through the cartilage depth) on medial or lateral femoral condyles 4. Cartilage lesion area < 3.2 cm2 (diameter < 2 cm) 5. Failed earlier conservative or surgical interventions such as lavage, abrasions, drilling or microfracture 6. VAS-pain symptom >40 for more than 6 months 7. The arthroscopic finding corresponds to the expected; size of cartilage lesion is correct and no other significant pathology (see CIP, "Intra-operative check-list", Appendix I) 8. Capable of completing self-administered questionnaires 9. Willing to comply with the follow-up requirements of the study 10. Signed informed consent Exclusion Criteria: 1. BMI = 35 kg/m2 (severe obesity) 2. Instability or deficiency of soft tissues, vascular or muscular insufficiency 3. Metabolic disorders which may impair bone formation 4. Diabetes mellitus 5. Smokers 6. Diagnosis of a concomitant knee injury which the Investigator appreciates may interfere with study participation (i.e. may confound efficacy assessment or healing at the involved knee joint level) 7. Irresolvable joint pain or loss-of-function with an undeterminable cause 8. Diagnosis of a concomitant meniscal injury in involved knee that requires surgical intervention 9. Loss of joint space on standing radiographs (= 1 on Ahlbäck-scale (0-5)) 10. Avascular necrosis 11. Infections, systemic or local 12. Known metal allergies 13. History of inflammatory arthritis 14. Pregnancy 15. Pacemaker implant 16. History of drug or substance abuse 17. Systemic administration within 30 days prior to the study of any type of corticosteroid, antineoplastics, immune stimulating or immunosuppressive agents 18. Participation in another clinical trial using an investigational new drug or device within 30 days of entrance into this study. 19. Condition that may have an impact on the outcome of the investigation as judged by the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Implant surgery
surgery

Locations

Country Name City State
Sweden Lund University Hospital, Department of Ortopedics Lund
Sweden Aleris Specialistvård Stockholm
Sweden Sports Medicine Umeå Umeå

Sponsors (1)

Lead Sponsor Collaborator
Episurf Medical Inc.

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with Adverse Events The primary efficacy analysis in this study is to ascertain that the incidence of at least one subject having any of the seven identified clinical undesirable side effects is lower than 38 % (risk profile of the comparator) up to the 24 months analysis in the PP population. This will be analyzed with a one-side exact binomial test on significance level 0.05 24 months
Secondary Clinical performance Clinical performance, by questionnaires and knee ROM measurements. 24 months
See also
  Status Clinical Trial Phase
Completed NCT05424848 - Femoral Cartilage Thickness in Parkinson's Disease
Terminated NCT01400607 - Neocartilage Implant to Treat Cartilage Lesions of the Knee Phase 3
Terminated NCT01410136 - Chondrofix Osteochondral Allograft Prospective Study N/A